Guggenheim Increases Price Target for Eli Lilly Amid Acquisition Activity
Guggenheim raised its price target for Eli Lilly (LLY) to $1,183 from $1,163, maintaining a 'Buy' rating, citing the company's acquisition of Centessa Pharmaceuticals and Kelonia Therapeutics. The move comes as analysts remain optimistic about Eli Lilly's growth prospects, with a consensus price target of $1,250, suggesting a potential 40% increase from current levels.
Tickers: $LLY
Topics: acquisitions analyst upgrade Eli Lilly pharmaceutical industry price target